Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab

NCT04533737 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

113

Enrollment

INDUSTRY

Sponsor class

Stopped The recruitment was terminated early due to delays and slow recruitment that significantly jeopardized the trial timelines. There were no safety concerns related to the early termination of the trial.

Conditions

Plaque Psoriasis
Psoriasis Vulgaris
Psoriasis

Interventions

BIOLOGICAL: Brodalumab
OTHER: Placebo
BIOLOGICAL: Guselkumab

Sponsor

LEO Pharma